October 8, 2019
MONROE, NY – On October 4, 2019, Innovative Health Sciences LLC (“IHS” or the “Company”) appointed Jeff Craven, Esq. IHS’ Chief Business Officer, to Interim CEO, replacing Mr. Andrew Sealfon. The Company also announced the formation of a Board of Directors and an Advisory Board, appointing Mr. Andrew Sealfon as the Chairman of the Board of Directors and Dr. Fred Ma as the Chairman of the Advisory Board.
“We are pleased to announce Mr. Craven’s new role as Interim CEO. Since joining IHS in July 2019, he has been integral to the company’s growth and management, providing wise counsel and support,” said Dr. Fred Ma, the company’s President and COO. Mr. Craven will now lead and manage the company’s fundraising activities and investor relations. He brings over 30 years of experience providing legal counsel as well as operating as a business adviser to his clients and helping them to establish effective business structures and strategic partnerships. Mr. Craven has successfully led negotiations and operations on mergers/acquisitions, fundraising, and IP filings.
“I am beyond excited for this new role with Innovative Health Sciences. With this new assignment, I will help IHS become a principle medical device provider in the home infusion industry,” Mr. Craven stated.
In alignment with the Company’s long-term objectives is the formation of the Board of Directors and the Advisory Board. Mr. Andrew Sealfon, Chief Technology Officer, is the newly appointed Chairman of the Board of Directors. Dr. Fred Ma, President/COO is the newly appointed Chairman of the Advisory Board and will manage a team of clinicians, Key Opinion Leaders, scientists, and industry professionals, who will work together on new infusion devices to promote industry standards, improved quality of life for patients and spread awareness of the latest industry news and clinical breakthroughs.
About Innovative Health Sciences
Innovative Health Sciences, LLC (located in Monroe, NY), is a newly established medical device company focused on developing and commercializing the home infusion device industry using state-of-the-art, proprietary technology, and innovative Intellectual Property (“IP”), with the goal of creating a “one-stop shop” solution for the home infusion industry. IHS intends to optimize the infusion of medications by focusing on patient outcomes and perfecting the science and education of device technologies. IHS is currently developing new infusion technologies for SCIg treatment that will dramatically improve patient outcomes and will re-invent the home infusion therapy business. IHS intends to bridge the gap between infusion medications (Pharma) and infusion systems (Device Manufacturers) through the innovative combination of pharmacokinetics and fluidics.
Forward Looking Statements
The statements contained herein do not guarantee future performance and undue reliance should not be placed on them. Such Forward Looking Statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied. These statements are based on management’s beliefs and theory. The Company undertakes no obligation to update Forward Looking Statements if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws.
Innovative Health Sciences, LLC